


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claim 1 (Currently Amended)** A compound of formula I



in which

$R^1$  is H, OH, CN, Hal, CONHR, OB,  $CO_2B$ ,  $CF_3$ ,  $NR_2$ , NRCOR, NRCOOR or  $NRCONR_2$ ,

$R^2$  is  $NR_2$ , NRCOR, NRCOOR, NRCONR<sub>2</sub>,  $NO_2$ ,  $NRSO_2R_2$ , NRCSR or NRCSNR<sub>2</sub>,

$R^3$  is H, OH, CN, Hal, CONHR, OB,  $CO_2B$ ,  $CF_3$ ,  $NO_2$ ,  $NR_2$ , NRCOR, NRCOOR or NRCONR<sub>2</sub>,

$R$ , independently of one another, are H, B, Het or Ar,

$A$  is a straight-chain or branched, mono- or polyunsaturated carbon chain having 2, 3, 4, 5, or 6 carbon atoms,

$B$  is a straight-chain or branched alkyl radical having 1, 2, 3, 4, 5 or 6 carbon atoms,

a pharmaceutically usable prodrug, derivative, salt thereof, or a mixture thereof in all ratios.

**Claim 2 (Previously Presented)** A compound of formula I according to  
Claim 1, wherein R<sup>1</sup> is CN or Hal.

**Claim 3 (Previously Presented)** A compound of formula I according to  
Claim 1, wherein R<sup>3</sup> is H.

**Claim 4 (Previously Presented)** A compound of formula I according to  
Claim 1 wherein R<sup>2</sup> is NRCOR or NRCOOR.

**Claim 5 (Previously Presented)** A compound of formula I according to  
Claim 1, wherein A is (CH<sub>2</sub>)<sub>m</sub>, where m = 2, 3, 4, 5 or 6.

**Claim 6 (Previously Presented)** A compound of formula I according to  
Claim 1, wherein R<sup>1</sup> is CN or Hal, and R<sup>3</sup> is H.

**Claim 7 (Previously Presented)** A compound of the formula I according to  
Claim 1, wherein R<sup>1</sup> is CN, R<sup>3</sup> is H, and A is (CH<sub>2</sub>)<sub>m</sub>, where m = 4.

**Claim 8 (Previously Presented)** A compound of formula I according to  
Claim 1, wherein R<sup>1</sup> is in position 5 of the indole radical.

**Claim 9 (Currently Amended)** A compound of formula I which is  
N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-  
yl)methylamide,

ethyl (6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-  
yl)carbamate,


methyl N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)-2,2-dimethylpropionamide,


3-{4-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]butyl}-1H-indole-5-carbonitrile,

or a pharmaceutically usable prodrug, derivative, solvate, stereoisomer or salt thereof.

**Claim 10 (Previously Presented)** A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula II




in which R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1, with a compound of formula III




in which R<sup>1</sup> and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

**Claim 11 (Previously Presented)** A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula IV



in which R<sup>3</sup> is as defined in Claim 1, and R<sup>4</sup> is an amino-protecting group or H, in a Michael-analogous reaction, with ethyl nitroacetate and diethylammonium chloride, and subsequently reducing the nitro group to give a compound of formula V



and reacting the compound of formula V is reacted with a compound conforming to formula III.

**Claim 12 (Canceled)**

**Claim 13 (Previously Presented)** A pharmaceutical composition, comprising an effective amount of a compound of the formula I according to Claim 1, optionally in addition to one or more inert excipients, adjuvants and/or diluents, and a pharmaceutically acceptable carrier.

**Claim 14 (Canceled)**

**Claim 15 (Currently Amended)** A process for the preparation of a composition according to Claim 13, comprising combining a compound of formula I ~~and, optionally, a further medicament active ingredient is incorporated into~~ with one or more inert excipients and/or diluents by non-chemical methods.

**Claim 16 (Canceled)**

**Claim 17 (Previously Presented)** A method for treating depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain or spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, or sexual dysfunctions, comprising administering to a host in need thereof a compound according to Claim 1.

**Claim 18 (Canceled)**

**Claim 19. (Previously Presented)** A method for treating depression, strokes, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, or Alzheimer's disease, comprising administering to a host in need thereof a compound according to Claim 1.